Quantcast

Latest Lipoproteins Stories

2014-09-15 12:27:24

Expert Panel Re-affirms the Importance of Setting Cholesterol Goals for the Prevention of Heart Attack and Stroke NEW YORK, Sept. 15, 2014 /PRNewswire/ -- Today, the National Lipid Association (NLA) released new recommendations based on a panel of independent experts, published in the Journal of Clinical Lipidology. The recommendations highlight the importance of doctors and patients setting cholesterol goals and focusing on patient's risk and risk factors, rather than on specific...

2014-09-15 08:26:44

INDIANAPOLIS, Sept. 15, 2014 /PRNewswire/ -- Chek Diagnostics, the U.S.-based manufacturer of both the CardioChek® brand and the A1CNow® family of point-of-care diagnostic products, has again been named to the Inc. 5000 list of the fastest-growing private companies in America. The Inc. 5000 ranking is based on revenue growth over a three-year period. Chek Diagnostics earned its place on the list by growing its revenue by 80 percent from 2010 to 2013....

2014-09-10 23:11:45

According to the Center for Disease Control and Prevention, approximately one in every six Americans has high cholesterol. New York Times and USA Today Best Selling author, Sanjay Jain, M.D. MBA explains how to identify signs of high cholesterol and reduce cholesterol levels without the use of expensive medications. Washington, DC (PRWEB) September 10, 2014 Recent statistics from the Center for Disease Control and Prevention show that 17% of Americans--one out of every six adults--have...

2014-09-10 16:26:00

WOODBRIDGE, ON, Sept. 10, 2014 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ("Pivotal" or the "Company"), a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease ("CVD") and overall health, announced today the publication of results of a prospective randomized controlled trial in the U.S. that evaluated the effects of VASCAZEN(®) in the correction of Omega-3 deficiency in patients with one or more risk factors associated...

2014-09-08 23:01:21

Free Mount Sinai Health System Cholesterol Fairs in September to Raise Awareness About the Importance of Maintaining Healthy Cholesterol Levels New York, NY (PRWEB) September 08, 2014 This September the Mount Sinai Health System will host five, free cholesterol fairs in honor of National Cholesterol Education Month. The effort is meant to increase awareness about the importance of maintaining healthy cholesterol levels to prevent cardiovascular diseases and stroke, and to promote a daily...

heart attack protein
2014-09-04 03:00:00

Vincent Lamontagne, University of Ottawa Heart Institute A team of researchers at the University of Ottawa Heart Institute, led by Dr. Alexandre Stewart, have uncovered an intriguing link between heart attacks and a protein that is of great interest to drug companies for its impact on cholesterol. The team found that levels of the protein PCSK9 were elevated in the blood of patients having an acute heart attack, but not in those who never had a heart attack or who had recovered from one...

2014-09-02 08:30:49

Presented in 'State of the Art and Featured Research Session' at the 2014 European Society of Cardiology Congress TSX Exchange Symbol: RVX BARCELONA, Spain and CALGARY, AB, Sept. 2, 2014 /PRNewswire/ - Resverlogix Corp. (TSX: RVX) announced today that Dr. Jan Johansson, senior vice president of medical affairs at Resverlogix delivered an oral presentation at the 2014 European Society of Cardiology (ESC) Congress in Barcelona, Spain. In his presentation, entitled: 'Effects of...

2014-09-02 08:30:18

TEL-AVIV, Israel, Sept. 2, 2014 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed"), a clinical-stage biopharmaceutical company focused on the development and commercialization of a once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones, announced today that it successfully completed two six-month chronic toxicology studies of its drug candidate, aramchol. These studies were performed in compliance with the European Medicines Agency's...

2014-08-28 08:28:39

Study Meets Co-Primary Endpoints of LDL Cholesterol Reduction THOUSAND OAKS, Calif., Aug. 28, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the Phase 3 YUKAWA-2 (StudY of LDL-Cholesterol Reduction Using a Monoclonal PCSK9 Antibody in Japanese Patients With Advanced Cardiovascular Risk) study evaluating evolocumab in combination with statin therapy in Japanese patients with high cardiovascular risk and high cholesterol met its co-primary endpoints: the percent...

2014-08-28 08:27:42

CARLSBAD, Calif., Aug. 28, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced the initiation of a Phase 3 study evaluating ISIS-APOCIII(Rx) in patients with familial chylomicronemia syndrome (FCS). FCS is a rare orphan disease, characterized by extremely high triglyceride levels, that affects an estimated 3,000 to 5,000 patients worldwide. The Phase 3 study of ISIS-APOCIII(Rx) is a randomized, double-blind, placebo-controlled, six month study in approximately...


Word of the Day
jument
  • A beast of burden; also, a beast in general.
'Jument' ultimately comes from the Latin 'jugum,' yoke.
Related